액상형 PRF, Injectable PRF, i-PRF, 스티키본

Clin Oral Investig. 2017 Feb 2. doi: 10.1007/s00784-017-2063-9. [Epub ahead of print]

Injectable platelet rich fibrin (i-PRF): opportunities in regenerative dentistry?

Miron RJ^1,2,3, Fujioka-Kobayashi M^4,5,6, Hernandez M⁴, Kandalam U⁷, Zhang Y⁸, Ghanaati S⁹, Choukroun J¹⁰.

Author information

1

Department of Periodontology, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA. rmiron@nova.edu.

2

Cell Therapy Institute, Center for Collaborative Research, Nova Southeastern University, Fort Lauderdale, FL, USA. rmiron@nova.edu.

3

Department of Periodontics and Oral Medicine, University of Michigan, Ann Arbor, MI, USA. rmiron@nova.edu.

4

Department of Periodontology, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA.

5

Department of Cranio-Maxillofacial Surgery, University of Bern, Bern, Switzerland.

6

Department of Oral Surgery, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.

7

Department of Pediatric Dentistry, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA.

8

Department of Oral Implantology, University of Wuhan, Wuhan, China.

9

FORM, Frankfurt Oral Regenerative Medicine, Clinic for Maxillofacial and Plastic Surgery, Johann Wolfgang Goethe University, Frankfurt Am Main, Germany.

10

Pain Clinic, Nice, France.

Abstract

OBJECTIVES:

Platelet rich plasma (PRP) has been utilized in regenerative dentistry as a supra-physiological concentrate of autologous growth factors capable of stimulating tissue regeneration. Despite this, concerns have been expressed regarding the use of anti-coagulants, agents known to inhibit wound healing. In this study, a liquid formulation of platelet rich fibrin (PRF) termed injectable-PRF (i-PRF) without the use of anti-coagulants was investigated.

MATERIALS AND METHODS:

Standard PRP and i-PRF (centrifuged at 700 rpm (60G) for 3 min) were compared for growth factor release up to 10 days (8 donor samples). Furthermore, fibroblast biocompatibility at 24 h (live/dead assay); migration at 24 h; proliferation at 1, 3, and 5 days, and ｅxpression of PDGF, TGF-β, and collagen1 at 3 and 7 days were investigated.

RESULTS:

Growth factor release demonstrated that in general PRP had higher early release of growth factors whereas i-PRF showed significantly higher levels of total long-term release of PDGF-AA, PDGF-AB, EGF, and IGF-1 after 10 days. PRP showed higher levels of TGF-β1 and VEGF at 10 days. While both formulations exhibited high biocompatibility and higher fibroblast migration and proliferation when compared to control tissue-culture plastic, i-PRF induced significantly highest migration whereas PRP demonstrated significantly highest cellular proliferation. Furthermore, i-PRF showed significantly highest mRNA levels of TGF-β at 7 days, PDGF at 3 days, and collagen1 ｅxpression at both 3 and 7 days when compared to PRP.

CONCLUSIONS:

i-PRF demonstrated the ability to release higher concentrations of various growth factors and induced higher fibroblast migration and ｅxpression of PDGF, TGF-β, and collagen1. Future animal research is now necessary to further validate the use of i-PRF as a bioactive agent capable of stimulating tissue regeneration.

CLINICAL RELEVANCE:

The findings from the present study demonstrate that a potent formulation of liquid platelet concentrates could be obtained without use of anti-coagulants.

KEYWORDS:

Blood platelets; Fibrin; Fibroblasts; Platelet rich fibrin; Regeneration; Wound healing